Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Tyme Technologies Inc    TYME

TYME TECHNOLOGIES INC (TYME)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
3.66(c) 3.65(c) 3.41(c) 3.56(c) 3.5(c) Last
153 423 62 549 193 036 163 628 161 621 Volume
-8.27% -0.27% -6.58% +4.40% -1.69% Change
More quotes
Company
Tyme Technologies, Inc. is a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications.Its lead investigational candidate, SM-88, is a novel first-in-class therapy that is designed to use... 
Sector
Biotechnology & Medical Research
Calendar
02/22 | 02:30pmPresentation
More about the company
Latest news on TYME TECHNOLOGIES INC
02/15TYME TECHNOLOGIES : to Present at RBC Capital Markets 2018 Global Healthcare Con..
AQ
02/13TYME TECHNOLOGIES : to Present at RBC Capital Markets 2018 Global Healthcare Con..
AQ
02/12TYME TECHNOLOGIES : Announces Interim Phase II Safety and Efficacy Data for SM-8..
AQ
02/09TYME TECHNOLOGIES, INC. : Other Events (form 8-K)
AQ
02/08Tyme Announces Interim Phase II Safety and Efficacy Data for SM-88 in Prostat..
GL
02/07Tyme Provides Clinical and Corporate Update for Fiscal Third Quarter 2017
GL
02/07TYME TECHNOLOGIES : Management's Discussion and Analysis of Financial Condition ..
AQ
02/01TYME TECHNOLOGIES : Announces Prostate Cancer Collaboration with Dr. Mack Roach ..
AQ
01/30Tyme Announces Prostate Cancer Collaboration with Dr. Mack Roach III of UCSF
GL
01/24TYME TECHNOLOGIES : Announces Positive Efficacy Data for SM-88 in Pancreatic Can..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/15Insider Selling: Tyme Technologies Inc $TYME CEO Sells 17,986 Shares of Stock.. 
02/15$TYME - Insider Selling: Tyme Technologies Inc #TYME CEO Sells 17,986 Shares .. 
02/15Tyme Technologies $TYME Downgraded to “Sell” at Zacks Investment Research  
02/12Tyme Technologies $TYME Earns Daily News Impact Score of 0.12  
02/08Tyme's lead candidate SM-88 shows treatment effect in mid-stage prostate canc.. 
More tweets
Qtime:17
News from SeekingAlpha
02/09YOUR DAILY PHARMA SCOOP : Adamas' Gocovri Key Value Driver, BioMarin Data, Regen.. 
02/08Tyme's lead candidate SM-88 shows treatment effect in mid-stage prostate canc.. 
01/23YOUR DAILY PHARMA SCOOP : Omeros' OMS721, Celgene To Acquire Juno, BioCryst And .. 
01/19Tyme Tech's lead candidate shows positive effect in early-stage pancreatic ca.. 
01/12Tyme Technologies (TYME) Presents At 36th Annual J.P. Morgan Healthcare Confe.. 
Chart TYME TECHNOLOGIES INC
Duration : Period :
Tyme Technologies Inc Technical Analysis Chart | TYME | US90238J1034 | 4-Traders
Technical analysis trends TYME TECHNOLOGIES INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Managers
NameTitle
Steve Hoffman Chief Executive Officer & Director
Ben Taylor President & Chief Financial Officer
Michael Demurjian Chief Operating Officer, Director & Executive VP
Guiseppe Del Priore Chief Medical Officer
Jonathan M. Eckard Chief Scientific Affairs Officer
Sector and Competitors
1st jan.Capitalization (M$)
TYME TECHNOLOGIES INC-46.55%305
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055